1. Single-Cell and Bulk Transcriptomics Reveal the Immunosenescence Signature for Prognosis and Immunotherapy in Lung Cancer.
- Author
-
Zhang, Yakun, Zhou, Jiajun, Jin, Yitong, Liu, Chenyu, Zhou, Hanxiao, Sun, Yue, Jiang, Han, Gan, Jing, Zhang, Caiyu, Lu, Qianyi, Chang, Yetong, Zhang, Yunpeng, Li, Xia, and Ning, Shangwei
- Subjects
- *
TREATMENT of lung tumors , *RESEARCH funding , *IMMUNOTHERAPY , *IMMUNE system , *TUMOR markers , *IMMUNE checkpoint inhibitors , *LUNG tumors , *AGING , *GENE expression profiling , *SURVIVAL analysis (Biometry) , *DISEASE progression - Abstract
Simple Summary: Immunosenescence is the decrease in the function of the immune system with age. The immune system plays a key role in the development and progression of tumors. Targeting immunosenescence is considered a promising therapeutic approach to improving tumor prognosis. However, few studies have been conducted to reveal immunosenescence biomarkers of lung cancer. Thus, our study aimed to fill this critical knowledge gap by developing an immunosenescence gene set to characterize tumor immune microenvironment and proposing an immunosenescence risk model to understand the roles of immunosenescence in tumor prognosis and immunotherapy. Background: Immunosenescence is the aging of the immune system, which is closely related to the development and prognosis of lung cancer. Targeting immunosenescence is considered a promising therapeutic approach. Methods: We defined an immunosenescence gene set (ISGS) and examined it across 33 TCGA tumor types and 29 GTEx normal tissues. We explored the 46,993 single cells of two lung cancer datasets. The immunosenescence risk model (ISRM) was constructed in TCGA LUAD by network analysis, immune infiltration analysis, and lasso regression and validated by survival analysis, cox regression, and nomogram in four lung cancer cohorts. The predictive ability of ISRM for drug response and immunotherapy was detected by the oncopredict algorithm and XGBoost model. Results: We found that senescent lung tissues were significantly enriched in ISGS and revealed the heterogeneity of immunosenescence in pan-cancer. Single-cell and bulk transcriptomics characterized the distinct immune microenvironment between old and young lung cancer. The ISGS network revealed the crucial function modules and transcription factors. Multiplatform analysis revealed specific associations between immunosenescence and the tumor progression of lung cancer. The ISRM consisted of five risk genes (CD40LG, IL7, CX3CR1, TLR3, and TLR2), which improved the prognostic stratification of lung cancer across multiple datasets. The ISRM showed robustness in immunotherapy and anti-tumor therapy. We found that lung cancer patients with a high-risk score showed worse survival and lower expression of immune checkpoints, which were resistant to immunotherapy. Conclusions: Our study performed a comprehensive framework for assessing immunosenescence levels and provided insights into the role of immunosenescence in cancer prognosis and biomarker discovery. [ABSTRACT FROM AUTHOR]
- Published
- 2025
- Full Text
- View/download PDF